23:31 , Jul 16, 2019 |  BC Extra  |  Company News

Genentech adds three discovery partnerships to build out pipeline

Through a trio of deals with Convelo, Skyhawk and Sosei Heptares announced Tuesday, Genentech is adding programs that could refresh its early stage neurology pipeline, as well as its oncology and other early R&D. Global...
20:56 , Jul 15, 2019 |  BC Extra  |  Company News

July 15 Company Quick Takes: Boehringer takes out cancer vaccine company Amal; plus Farxiga setback, Alkermes and more

Boehringer buying cancer vaccine play Amal  Boehringer Ingelheim (Ingelheim, Germany) is acquiring Amal Therapeutics S.A. (Geneva, Switzerland), a University of Geneva spinout developing cancer vaccines. Amal's shareholders will receive an undisclosed upfront payment; the total...
00:19 , Jul 12, 2019 |  BC Extra  |  Clinical News

Amyloid hypothesis takes first hit in an Alzheimer’s prevention setting

With Novartis and Amgen’s decision to halt a pair of trials in presymptomatic Alzheimer’s patients Thursday, what was widely considered the only setting left for the amyloid hypothesis in the disease took a blow. Amyloid-lowering...
22:59 , Jul 8, 2019 |  BC Extra  |  Company News

July 8 Company Quick Takes: Merck, Skyhawk in discovery deal; plus MorphoSys, BioMarin, Roche-Spark and Hanmi

Skyhawk, Merck in neurology, cancer deal  Skyhawk Therapeutics Inc. (Waltham, Mass.) and Merck & Co. Inc. (NYSE:MRK) parterned to discover, develop and commercialize small molecules capable of modulating RNA splicing discovered using Skyhawk’s SkySTAR platform...
00:22 , Jul 2, 2019 |  BC Extra  |  Clinical News

Biogen's Spinraza yields long-term preservation of motor development in SMA

Gearing up to compete with a gene therapy in SMA, Biogen presented long-term data from its antisense therapy Spinraza that could help make the case for continued use of the chronic treatment. In the open-label...
01:39 , Jun 29, 2019 |  BioCentury  |  Finance

Specialists and strong fundamentals must carry the sector in 3Q19

Heading into the third quarter, specialist biotech investors are in the driver’s seat, and their stances on whether to trim or spend in the down market are split. After recovering at the start of the...
01:17 , Jun 29, 2019 |  BC Extra  |  Company News

Management tracks: Carrick names Pearson CEO in U.S. push; plus AC Immune, Paratek and more

Cancer company Carrick Therapeutics Ltd. (Dublin, Ireland) hired Tim Pearson as CEO. He succeeds Elaine Sullivan, one of the company's founders, who will become executive entrepreneur and an adviser to the board. Pearson, who was...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
21:02 , Jun 27, 2019 |  BC Extra  |  Financial News

Syncona reaps tenfold return from Blue Earth exit

Returns from the sale of Blue Earth Diagnostics for $450 million will allow majority shareholder Syncona to reinvest in its maturing portfolio companies as they scale, and will also drive new company launches, the firm's...
23:28 , Jun 26, 2019 |  BC Innovations  |  Distillery Therapeutics

Induction of NFE2L2 activity for Alzheimer's disease

DISEASE CATEGORY: Neurology INDICATION: Alzheimer's disease (AD) Inducers of NFE2L2 activity could help treat AD. Postmortem brain tissue from seven AD patients had lower NFE2L2 protein levels than tissue from seven control donors, and low...